Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,220 shares of the medical research company's stock after acquiring an additional 1,696 shares during the period. ProShare Advisors LLC's holdings in Thermo Fisher Scientific were worth $30,288,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Stonegate Investment Group LLC increased its position in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock valued at $3,531,000 after acquiring an additional 18 shares during the period. Semus Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 4.0% during the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after acquiring an additional 18 shares in the last quarter. Eagle Rock Investment Company LLC lifted its stake in Thermo Fisher Scientific by 0.3% in the 4th quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock valued at $3,882,000 after buying an additional 19 shares in the last quarter. KRS Capital Management LLC lifted its stake in Thermo Fisher Scientific by 1.5% in the 4th quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock valued at $685,000 after buying an additional 20 shares in the last quarter. Finally, Evernest Financial Advisors LLC lifted its stake in Thermo Fisher Scientific by 4.0% in the 4th quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company's stock valued at $271,000 after buying an additional 20 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,075 shares of company stock valued at $7,305,942. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO traded down $0.45 during mid-day trading on Tuesday, reaching $413.47. 2,141,884 shares of the company's stock were exchanged, compared to its average volume of 1,845,527. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company has a 50-day simple moving average of $451.89 and a two-hundred day simple moving average of $508.88. Thermo Fisher Scientific Inc. has a 52-week low of $390.50 and a 52-week high of $627.88. The company has a market cap of $156.08 billion, a price-to-earnings ratio of 25.01, a PEG ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm's revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business posted $5.11 earnings per share. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.42%. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TMO. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. UBS Group reduced their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Citigroup cut their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $607.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.